Japanese scientists at Nara Medical University have developed an artificial blood that works for all blood types and can be stored for up to two years at room temperature, potentially solving critical challenges in emergency medicine and blood supply management worldwide.
Purple Artificial Hemoglobin
Unlike natural blood’s familiar red color, this revolutionary artificial blood is distinctively purple. This unusual hue results from the special processing of hemoglobin, the oxygen-carrying component of red blood cells. The manufacturing process involves extracting hemoglobin from expired donated blood, then encapsulating it in a protective lipid membrane. This encapsulation technique not only creates virus-proof artificial red blood cells but also removes the cell membrane that typically contains blood type antigens. The absence of these antigens is what enables the blood to be universally compatible with all patients regardless of their blood type, representing a significant advancement in transfusion medicine.
Two-Year Room Temperature Storage
The artificial blood developed by Japanese researchers offers remarkable storage capabilities that far exceed conventional blood products. While traditional donated red blood cells require refrigeration and expire after just 42 days, this synthetic alternative can be stored at room temperature for up to two years and potentially up to five years under refrigeration. This extended shelf life represents a revolutionary advancement for emergency medicine, particularly in remote locations, conflict zones, and disaster areas where maintaining cold chain logistics is challenging or impossible.
This storage breakthrough addresses one of the most significant limitations in blood supply management worldwide. The room-temperature stability eliminates the need for specialized refrigeration equipment, making the artificial blood ideal for field hospitals, ambulances, and crisis zones. For comparison, platelets in traditional blood can only be stored at room temperature for five days, highlighting how transformative this technology could be for global healthcare systems, especially in low and middle-income countries where maintaining adequate blood supplies is particularly difficult.
Hemoglobin Vesicles Technology
Hemoglobin vesicles (HbV) represent the core technology behind this artificial blood substitute. These cellular-structured carriers encapsulate highly concentrated hemoglobin solution (35 g/dL) within phospholipid bilayer membranes (liposomes), effectively mimicking the structure of natural red blood cells. The liposomal membrane surface is covered with polyethylene glycol (PEG), which shields the toxic effects of free hemoglobin that would otherwise cause renal and cardiovascular damage if released directly into circulation.
The production process has evolved significantly, with researchers developing an efficient kneading method using a rotation-revolution mixer that dramatically increases hemoglobin encapsulation efficiency to 74.2%, compared to just 20% with conventional extrusion methods. This technological advancement has facilitated extensive research and development, culminating in a first-in-human phase 1 clinical trial conducted in 2020 to assess safety and pharmacokinetics. Beyond serving as a transfusion alternative, this versatile technology has been adapted for additional clinical applications, including the development of carbonyl-HbV and met-HbV as anti-inflammatory/anti-oxidative agents and antidotes for certain poisons.
